NeuroSense Therapeutics Ltd.

NasdaqCM:NRSN Stock Report

Market Cap: US$26.6m

NeuroSense Therapeutics Future Growth

Future criteria checks 0/6

NeuroSense Therapeutics is forecast to grow earnings and revenue by 55.4% and 62.1% per annum respectively while EPS is expected to grow by 60.9% per annum.

Key information

55.4%

Earnings growth rate

60.90%

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth rate62.1%
Future return on equityn/a
Analyst coverage

Low

Last updated21 May 2026

Recent future growth updates

Recent updates

Analysis Article • Mar 22

NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Dec 06

Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 03

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Nov 17

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 31

NeuroSense Therapeutics GAAP EPS of -$0.55

NeuroSense Therapeutics press release (NASDAQ:NRSN): Q2 GAAP EPS of -$0.55. As of June 30, 2022, NeuroSense had cash and short-term deposits of $10.37M.
Analysis Article • Jul 06

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 30

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

Nanocap biotech NeuroSense Therapeutics (NASDAQ:NRSN) surged ~66% in the pre-market Thursday after the company announced results from a biomarker study supporting the effect of its experimental combination drug CogniC in patients with Alzheimer's disease (AD). Citing early results, NeuroSense (NRSN) pointed to high levels of a protein called TDP-43 in patients suffering from AD. NeuroSense's (NRSN) platform combination therapy technology, the basis of CogniC can impact TDP-43, the company said citing results from a Phase IIa clinical trial biomarker study targeted at amyotrophic lateral sclerosis (ALS). NeuroSense (NRSN) has planned clinical trials for CogniC in 2023. "Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic,” Chief Executive Alon Ben-Noon said.
Seeking Alpha • Mar 31

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

NRSN is a clinical-stage biotech developing therapeutics for neurodegenerative diseases, including ALS. The company's "PrimeC" drug candidate has shown promising efficacy results and is expected to start a Phase 2b. The stock looks interesting considering the opportunity and several expected catalysts through 2022.
Analysis Article • Mar 22

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 22

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

NeuroSense Therapeutics is advancing a breakthrough treatment for ALS and other neurodegenerative diseases. The Company’s approach is to target the multiple disease mechanisms in the CNS by combining therapeutic strategies. The Company’s lead candidate has been granted orphan drug designation in ALS by both the FDA and EMA.

Earnings and Revenue Growth Forecasts

NasdaqCM:NRSN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202810-4N/A-32
12/31/20274-25N/A-92
12/31/2026N/A-13N/A-122
12/31/2025N/A-11-8-8N/A
9/30/2025N/A-10N/AN/AN/A
6/30/2025N/A-9-8-8N/A
3/31/2025N/A-7N/AN/AN/A
12/31/2024N/A-10-10-10N/A
9/30/2024N/A-12N/AN/AN/A
6/30/2024N/A-10-10-10N/A
3/31/2024N/A-13N/AN/AN/A
12/31/2023N/A-10-8-8N/A
9/30/2023N/A-11N/AN/AN/A
6/30/2023N/A-11-7-7N/A
3/31/2023N/A-14N/AN/AN/A
12/31/2022N/A-10-8-8N/A
9/30/2022N/A-9N/AN/AN/A
6/30/2022N/A-7-5-5N/A
3/31/2022N/A-5N/AN/AN/A
12/31/2021N/A-3-2-2N/A
9/30/2021N/A-5N/AN/AN/A
6/30/2021N/A-5-1-1N/A
3/31/2021N/A-5N/AN/AN/A
12/31/2020N/A-3-1-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NRSN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NRSN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NRSN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NRSN is forecast to have no revenue next year.

High Growth Revenue: NRSN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NRSN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 06:09
End of Day Share Price 2026/06/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeuroSense Therapeutics Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Jason KolbertD. Boral Capital LLC.
Robert LeBoyerNOBLE Capital Markets, Inc.